Derma Sciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Derma Sciences, Inc.
Deal Watch: AstraZeneca Out-Licenses Pneumonia Candidate, Obtains STING Inhibitors
Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.
M&A Analysis: Steady Goes September
Medtech M&A deal making has resumed the pace of activity seen before the brief surge in the summer. 17 M&A deals were announced and recorded on the Medtech Insight M&A deal tracker, one more than the previous month but included a few billion dollar transactions.
Integra Thinks High Margin, Differentiated Portfolio Can Deliver A Transformative 2017
Integra LifeSciences surged to industry-leading 12% sales growth in 2016, and that's before it prepares to consolidate two of the biggest acquisitions in its history. What is the strategy behind the success of the specialty surgery, orthopedics and tissue tech company that is looking at another double-digit sales uplift in 2017?
In Vivo's Deals Of The Month, February 2017
Free article: In Vivo's editors pick February's most significant deals, including Seattle Genetics' new ADC and Integra's big bid in neurosurgery.
- Medical Devices
- Other Names / Subsidiaries
- BioD, LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.